Clinical Trial

A Study of MBS314 in Participants With Relapsed/Refractory Multiple Myeloma.

Recruiting Phase 1/2
View on ClinicalTrials.gov →
Record status
This record was last updated March 15, 2024 (before its estimated February 2026 completion). Its status may not reflect the trial's current state.
Summary
This is a Phase I/Ⅱ, multicenter, open-label, dose-escalation study designed to evaluate the safety, tolerability, pharmacokinetics (PK), pharmacodynamics(PD) and efficacy of a novel asymmetric trivalent tri-specific humanized antibody, MBS314, administered by intravenous (IV) infusion in participants with relapsed or refractory multiple myeloma. This entry-to-human study is divided in 2 parts: a dose escalation part (Phase Ⅰa) and an expansion part (Phase Ⅰb/Ⅱ).
Protocol Amendment History 3 amendments
This ClinicalTrials.gov record has been amended 3 times since 2024-01-22; most recent amendment 2024-03-14.
Status change: Not Yet Recruiting → Recruiting 2024-03-14
Trial Details
NCT Number NCT06232096
Lead Sponsor Beijing Mabworks Biotech Co., Ltd.
Conditions Relapsed or Refractory Multiple Myeloma
Enrollment 154 participants
Start Date 2024-02-22
Primary Completion 2026-02 (estimated)
Study Completion 2028-03 (estimated)
Updated on ClinicalTrials.gov 2024-03-15